22157.jpg
Somatostatin Analogs Market Report 2024: Global Trends, Forecast and Competitive Analysis to 2030 - Opportunities in the Acromegaly and Neuroendocrine Tumor Markets
February 16, 2024 05:18 ET | Research and Markets
Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
22157.jpg
Global Somatostatin Analogs Market to Reach $8.67 Billion by 2028 - Forecast Shows Rapid Growth in Asia-Pacific and Innovation Trends
January 25, 2024 05:42 ET | Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global market for somatostatin...
Global Neuroendocrine Tumor Treatment Market
Neuroendocrine Tumor Treatment Market Set to Surge with Innovative Therapies and Global Expansion
January 23, 2024 02:43 ET | Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumor Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The neuroendocrine tumor...
22157.jpg
Lutathera and Pepaxto Dominated the Peptide Drug Conjugates Market in 2022
October 18, 2023 10:03 ET | Research and Markets
Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By...
Global Somatostatin Analogs Market
Global Somatostatin Analogs Market Intelligence Report to 2027 - Featuring CVS Health, Ipsen Pharma and Pfizer Among Others
July 25, 2022 06:43 ET | Research and Markets
Dublin, July 25, 2022 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global...
22157.jpg
Global Neuroendocrine Tumors Market & Drug Forecast 2021-2030 | Most Important Unmet Needs and the Projected Impact of 5 Late-Stage Pipeline Agents Entering the Market
October 14, 2021 07:13 ET | Research and Markets
Dublin, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The market of...
22157.jpg
Global Neuroendocrine Tumors (NET) Market Spotlight 2020-2028
March 04, 2021 06:48 ET | Research and Markets
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Neuroendocrine tumors (NET)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the...
crinetics.png
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
September 21, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
November 26, 2019 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 16:04 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...